MA44993A - Polypeptides de fusion cd40l-fc et procédés d'utilisation associés - Google Patents

Polypeptides de fusion cd40l-fc et procédés d'utilisation associés

Info

Publication number
MA44993A
MA44993A MA044993A MA44993A MA44993A MA 44993 A MA44993 A MA 44993A MA 044993 A MA044993 A MA 044993A MA 44993 A MA44993 A MA 44993A MA 44993 A MA44993 A MA 44993A
Authority
MA
Morocco
Prior art keywords
cd40l
fusion polypeptides
associated procedures
procedures
polypeptides
Prior art date
Application number
MA044993A
Other languages
English (en)
Inventor
Manuel Baca
Stacey Drabic
Peter Emtage
Ronald Herbst
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MA44993A publication Critical patent/MA44993A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA044993A 2016-05-13 2017-05-12 Polypeptides de fusion cd40l-fc et procédés d'utilisation associés MA44993A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662336129P 2016-05-13 2016-05-13

Publications (1)

Publication Number Publication Date
MA44993A true MA44993A (fr) 2019-03-20

Family

ID=60267851

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044993A MA44993A (fr) 2016-05-13 2017-05-12 Polypeptides de fusion cd40l-fc et procédés d'utilisation associés

Country Status (18)

Country Link
US (1) US10975155B2 (fr)
EP (1) EP3455263A4 (fr)
JP (1) JP2019523636A (fr)
KR (1) KR20190004319A (fr)
CN (1) CN109153729A (fr)
AR (1) AR108468A1 (fr)
AU (1) AU2017264944A1 (fr)
BR (1) BR112018072953A2 (fr)
CA (1) CA3022636A1 (fr)
CL (1) CL2018003141A1 (fr)
CO (1) CO2018013104A2 (fr)
IL (1) IL262727A (fr)
MA (1) MA44993A (fr)
MX (1) MX2018013762A (fr)
RU (1) RU2018138703A (fr)
SG (1) SG11201809374VA (fr)
TW (1) TW201741337A (fr)
WO (1) WO2017197231A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2571879T3 (es) * 2008-07-21 2016-05-27 Apogenix Ag Moléculas de una sola cadena de TNFSF
PL3043816T3 (pl) * 2013-09-11 2020-03-31 Medimmune Limited Przeciwciała anty-b7-h1 do leczenia nowotworów
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
WO2018127918A1 (fr) 2017-01-05 2018-07-12 Kahr Medical Ltd. Protéine de fusion sirp alpha-cd70 et ses procédés d'utilisation
HRP20230937T1 (hr) 2017-01-05 2023-11-24 Kahr Medical Ltd. Pd1-41bbl fuzijski protein i metode korištenja istog
PT3565828T (pt) 2017-01-05 2022-02-08 Kahr Medical Ltd Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
WO2018127916A1 (fr) 2017-01-05 2018-07-12 Kahr Medical Ltd. Protéine de fusion pd1-cd70 et ses procédés d'utilisation
KR20210044220A (ko) 2018-07-11 2021-04-22 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
SG11202013170RA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd Pd1-4-1bbl variant fusion protein and methods of use thereof
WO2020163534A1 (fr) * 2019-02-06 2020-08-13 The Regents Of The University Of California Polypeptides cd40l négatifs dominants
WO2021006604A1 (fr) * 2019-07-08 2021-01-14 주식회사 프로젠 Nouvelle protéine de fusion et son utilisation
US12012453B2 (en) * 2019-09-05 2024-06-18 Astrazeneca Ab Methods for treating late-stage small cell lung cancer by administering a human anti-PD-L1 antibody, an etoposide and a platinum-based therapeutic
JP7807076B2 (ja) * 2019-12-13 2026-01-27 キュージーン インコーポレイテッド 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用
EP4186517A4 (fr) * 2020-01-23 2024-05-29 Genexine, Inc. Protéine de fusion comprenant une protéine pd-l1 et utilisation associée
WO2021248061A1 (fr) * 2020-06-04 2021-12-09 Carisma Therapeutics Inc. Nouvelles constructions pour récepteurs antigéniques chimériques
CA3213285A1 (fr) * 2021-03-12 2022-09-15 Janssen Biotech, Inc. Compositions de proteines de fusion immunomodulatrices obtenues par bio-ingenierie
WO2023088876A1 (fr) * 2021-11-16 2023-05-25 Apogenix Ag Modulateurs immunitaires multi-spécifiques
WO2024208936A1 (fr) 2023-04-05 2024-10-10 F. Hoffmann-La Roche Ag Procédé de culture in vitro pour cellules exprimant des anticorps
CN119613573B (zh) * 2025-02-14 2025-05-30 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途
CN120590545A (zh) * 2025-06-09 2025-09-05 上海市胸科医院 包括cd40l和il7的融合蛋白及其在制备治疗肿瘤药物中的应用
CN120943974A (zh) * 2025-07-31 2025-11-14 上海市胸科医院 Cd40l-il-21融合蛋白及其制备与在制备治疗肿瘤药物中的用途
CN120888000A (zh) * 2025-07-31 2025-11-04 上海市胸科医院 Cd40l-il-2融合蛋白及其制备与在制备治疗肿瘤药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693713B2 (en) * 1995-06-07 1998-07-02 Immunex Corporation CD40L mutein
CN1242809C (zh) * 1996-07-08 2006-02-22 纽约市哥伦比亚大学理事会 T－bam(cd40l)技术在制备治疗涉及平滑肌细胞的疾病的药物中的应用
US6774225B2 (en) 1999-04-15 2004-08-10 Hong Kong University Of Science & Technology Antigenized antibody vaccine for foot-and-mouth disease
ATE545703T1 (de) * 2000-07-25 2012-03-15 Immunomedics Inc Multivalentes zielbindendes protein
AU2002359780B2 (en) 2001-12-21 2009-08-13 Immunex Corporation Recombinant polypeptides
DK2444424T3 (en) 2005-05-20 2018-12-03 Ablynx Nv IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
ES2571879T3 (es) 2008-07-21 2016-05-27 Apogenix Ag Moléculas de una sola cadena de TNFSF
MA41460A (fr) * 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3292143B1 (fr) 2015-05-04 2019-08-21 Apogenix AG Protéines agonistes du récepteur cd40 à chaîne unique

Also Published As

Publication number Publication date
EP3455263A4 (fr) 2020-01-01
MX2018013762A (es) 2019-03-28
AU2017264944A1 (en) 2018-12-20
SG11201809374VA (en) 2018-11-29
AR108468A1 (es) 2018-08-22
CN109153729A (zh) 2019-01-04
RU2018138703A (ru) 2020-06-15
US20170327588A1 (en) 2017-11-16
IL262727A (en) 2018-12-31
CO2018013104A2 (es) 2018-12-14
TW201741337A (zh) 2017-12-01
BR112018072953A2 (pt) 2019-02-19
EP3455263A1 (fr) 2019-03-20
US10975155B2 (en) 2021-04-13
WO2017197231A1 (fr) 2017-11-16
JP2019523636A (ja) 2019-08-29
KR20190004319A (ko) 2019-01-11
CA3022636A1 (fr) 2017-11-16
CL2018003141A1 (es) 2018-12-28

Similar Documents

Publication Publication Date Title
MA44993A (fr) Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
EP3655006A4 (fr) Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation
MA44507A (fr) Récepteurs chimères de flt3 et leurs procédés d'utilisation
EP3504245A4 (fr) Polypeptides chimériques clivables de manière protéolytique et leurs procédés d'utilisation
IL263478A (en) Aerosol-generating system comprising a gel containing cartridge and a device for heating the cartridge
MA51291A (fr) Protéines de fusion il-2 fc modifiées
MA40721A (fr) Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
EP3430058A4 (fr) Protéines de fusion à fab multispécifiques et leur utilisation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
EP3390624A4 (fr) Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3349674A4 (fr) Systèmes et procédés d'espacement d'articulation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
EP3352760A4 (fr) Polypeptides de liaison à cd3
EP3680331A4 (fr) Protéine cas9 modifiée et utilisation de celle-ci
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
EP3538560A4 (fr) Polypeptides de fusion gdnf et leurs procédés d'utilisation
EP3621660A4 (fr) Compositions et procédés d'utilisation de capsides arc
EP3349851A4 (fr) Polypeptides photosensibles et leurs procédés d'utilisation
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation
EP3212290A4 (fr) Polypeptides de fusion de serpine et leurs procédés d'utilisation
EP3339320A4 (fr) Récepteur d'anticorps chimérique auquel est lié un anticorps anti-cotinine et utilisation de celui-ci
MA46059A (fr) Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation